GeoVax Labs (GOVX) Registration filing summary

Company overview and business model

• Clinical-stage biotech focused on vaccines and immunotherapies for infectious diseases and solid tumors using proprietary platforms.

• Lead programs: GEO-MVA (MVA-based vaccine for mpox/smallpox) and Gedeptin® (gene-directed therapy for head and neck cancers).

• GEO-MVA targets global supply constraints for orthopoxvirus vaccines, with expedited regulatory pathway in Europe and Phase 3 trial planned for H2 2026.

• Gedeptin® completed Phase 1/2; Phase 2 trial in combination with immune checkpoint inhibitor planned for H1 2027.

• Strategy includes advancing products to clinical testing, seeking partnerships for regulatory approval and commercialization, and leveraging collaborations.

Financial performance and metrics

• No product revenue to date; revenue derived from government grants and collaborations.

• Net loss of $21.5 million for 2025 and $5.3 million for Q1 2026.

• Research and development expenses were $18.1 million in 2025, down from $23.7 million in 2024.

• Cash and cash equivalents were $1.3 million as of March 31, 2026; sufficient to fund operations into August 2026.

• Received a going concern opinion from auditors due to recurring losses and need for additional funding.

Use of proceeds and capital allocation

• No proceeds from resale of shares by selling stockholders; proceeds from warrant exercises (if any) will be used for general corporate purposes and working capital.

• Pending use, proceeds will be invested in high-quality, short-term, interest-bearing securities.